Pre-exposure prophylaxis (PrEP) with daily antiretrovirals to prevent human immunodeficiency virus type 1 acquisition has not been shown to be consistently effective in cisgender women. Modeling adherence to daily PrEP clarifies how robust protection can be achieved.
- Mia Moore
- Sarah Stansfield
- Dobromir Dimitrov
